Boehringer Ingelheim starts Phase 2 trial of Gubra-originated triple agonist for obesity

Boehringer Ingelheim has begun a Phase 2 clinical trial of a triple receptor agonist for people living with overweight and obesity, according to an announcement from Gubra, the Danish peptide drug discovery company that originated the molecule ^[1]. The notice is dated July 16, 2026 ^[1].

Phase 2 is the middle stage of testing in people. It follows Phase 1, which mainly looks at safety and how a drug moves through the body, and it usually enrolls more participants while continuing to track side effects and looking for early signs of benefit. A Phase 2 result is not proof that a drug works, and the larger Phase 3 trials that regulators require before an approval decision have not been announced for this compound ^[1].

Gubra describes the experimental drug as a triple receptor agonist, meaning it is designed to act on three receptor targets rather than one ^[1]. Which three receptors the molecule targets has not been reported. The drug's name, its dose, the number of people the trial will enroll, how long it will run and when results might be released also have not been disclosed ^[1].

Boehringer Ingelheim is conducting the trial, while Gubra originated the molecule ^[1]. No financial terms tied to this specific trial were included in the announcement ^[1].

The triple agonist is not the only obesity candidate in the two companies' orbit. On March 9, 2026, Gubra reported Phase 1 results for a different partnered drug, ABBV-295, a long-acting amylin analog that AbbVie is developing for chronic weight management ^[1]. In the 12- to 13-week multiple-ascending-dose part of that study, average weight change ranged from -7.75% to -9.79% at week 12 for weekly dosing, and from -7.86% to -9.73% at week 13 for every-other-week and monthly dosing groups, compared with -0.26% and -0.25% for placebo ^[1]. The study enrolled 76 participants, tested doses from 2 mg to 14 mg, and was 88.3% male; the most common side effects were gastrointestinal disorders that were mostly mild and occurred mainly during the first six weeks, and no serious adverse events were reported ^[1]. ABBV-295 is described as non-incretin-based, a different class from GLP-1 and GIP receptor agonists ^[1]. It has not been approved by any regulatory authority, and its safety and efficacy have not been established ^[1].

Why it matters for patients

Nothing about the triple agonist is available to patients now, and the announcement does not change any treatment that is currently prescribed. The compound is in mid-stage testing, and any approval would depend on results from trials that have not started or been announced ^[1].

The announcement does not say whether the drug is a pill or an injection, how often it would be taken, or how it compares with existing options. Phase 2 trials are often where developers learn whether a tolerable dose can produce enough weight loss to justify larger studies.

The two programs show different strategies under study: the triple agonist is designed to hit three receptor targets at once, while ABBV-295 is an amylin analog that works outside the incretin pathway targeted by GLP-1 and GIP drugs ^[1]. Both remain experimental.

What happens next

No milestone dates have been announced for the triple agonist trial. Gubra has not disclosed a completion date, an enrollment target or a timeline for reporting results ^[1]. Full data from the ABBV-295 Phase 1 study are expected at a future scientific conference, a date that also has not been set ^[1].